Research programme: thrombosis therapies - SelecoreAlternative Names: Anti-platelet therapeutics - Selecore
Latest Information Update: 18 May 2011
At a glance
- Originator Selecore
- Class Proteins
- Mechanism of Action Platelet aggregation inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 07 Sep 2005 Preclinical trials in Thrombosis in Germany (PO)